로딩 중…
지수 로딩 중…
Vanda Pharmaceuticals Inc.
VNDA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$5.23+2.55%
2026-08-03
Financials
Valuation Metrics
Vanda Pharmaceuticals Inc.'s Market Cap is $315M. At end of 2025 it was $521M. Ranked #2952 of 3,112 in US market (top 95%), #1321 of 1,445 on NASDAQ (top 91%), #241 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $315M | US#2,952/3,112 Sec#241/269 |
| Revenue | $218M | US#2,658/3,112 Sec#110/269 |
| Net Income | $-240M | US—/3,112 Sec—/269 |
| Total Assets | $434M | US#2,799/3,112 Sec#176/269 |
| Net Assets | $281M | US#2,580/3,112 Sec#164/269 |
| Value | ||
| P/B | 1.12x | US#446/3,112 Sec#21/269 |
| P/S | 1.44x | US#944/3,112 Sec#17/269 |
| FCF Yield | -40.47% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -85.32% | US#2,834/3,112 Sec#214/269 |
| ROA | -55.26% | US#2,984/3,112 Sec#228/269 |
| Op. Margin | -73.64% | US#2,800/3,112 Sec#116/269 |
| Revenue Growth | 3.35% | US#1,911/3,112 Sec#116/269 |
| Financial Health | ||
| Debt Ratio | 54.41% | US#618/3,112 Sec#144/269 |
| Total Debt | $13M | US#2,758/3,112 Sec#191/269 |
| FCF | $-127M | US#2,640/3,112 Sec#171/269 |
| Cash | $54M | US#2,545/3,112 Sec#222/269 |
| Current Ratio | 2.16x | US#1,151/3,112 Sec#220/269 |
| Performance | ||
| 1Y Return | 24.82% | US#1,388/3,112 Sec#158/269 |
| 1M Return | -15.78% | US#2,842/3,112 Sec#209/269 |
| From 52W High | -47.38% | US#2,732/3,112 Sec#213/269 |
| 1Y MDD | -47.18% | US#2,282/3,112 Sec#176/269 |
| Trading | ||
| Volume | 699,736 shares | US#1,804/3,112 Sec#176/269 |
| Trading Value | $4M | US#2,767/3,112 Sec#227/269 |
| Per Share | ||
| EPS | $-3.73 | US—/3,112 Sec—/269 |
| BPS | $5.54 | US#2,178/3,112 Sec#123/269 |